What is the melanocortin receptor?
The melanocortin receptors are a family of five G-protein-coupled receptors (MC1R through MC5R) that bind the melanocortin peptide family — ACTH, α-MSH, β-MSH, and γ-MSH. The parent of KPV (a tripeptide derived from α-MSH) but the KPV pharmacology operates independently of melanocortin-receptor engagement.
What the research literature says
The five melanocortin receptors have distinct tissue distribution and ligand preferences. MC1R (skin melanocytes, mediating skin pigmentation), MC2R (adrenal cortex, the ACTH receptor), MC3R and MC4R (central nervous system, mediating appetite and energy-balance regulation), and MC5R (exocrine glands). Native α-MSH is the most potent ligand for MC1R and binds the other receptors at lower affinity.
KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val), retaining only the residues at positions 11-13 of the parent 13-amino-acid peptide. The tripeptide lacks the residues required for MC1R engagement and its published anti-inflammatory pharmacology operates independently of the melanocortin-receptor family — the Dalmasso PepT1-uptake characterisation and downstream NF-κB-modulation framework is mechanistically distinct from α-MSH’s melanocortin-receptor pharmacology (PMID 18061177).
The Kannengiesser IBD-research work documented anti-inflammatory potential of KPV without invoking melanocortin-receptor engagement (PMID 18092346). Researchers should distinguish KPV pharmacology from α-MSH or other melanocortin-receptor-engaging compounds.
Why this matters in research context
The melanocortin receptor family matters in peptide-research contexts for the broader α-MSH and ACTH pharmacology but does NOT meaningfully matter for KPV pharmacology specifically. The tripeptide’s published mechanism is PepT1-mediated intestinal-uptake plus NF-κB-pathway modulation, both operating without melanocortin-receptor engagement. The distinction matters for research-protocol design — protocols studying KPV pharmacology should not assume melanocortin-receptor-axis effects, and protocols studying α-MSH or other melanocortin-receptor-engaging compounds should not extrapolate from KPV findings as if they were class-representative. The two compound classes share a sequence ancestor but operate through fundamentally different mechanism pathways.
Related compounds
- KPV 10mg — derived from α-MSH but doesn’t engage MC receptors
Related research questions
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-178. [PMID 18061177]
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14(3):324-331. [PMID 18092346]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.